Zentalis Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ZNTL Nasdaq 2836 zentalis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress - Nov 10th, 2025 2:05 pm
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 3rd, 2025 3:25 pm
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - Nov 3rd, 2025 6:15 am
Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Oct 13th, 2025 2:05 pm
Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock - Oct 6th, 2025 9:39 am
Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary - Aug 26th, 2025 2:05 pm
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress - Aug 6th, 2025 2:05 pm
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is favoured by institutional owners who hold 59% of the company - Jul 23rd, 2025 10:34 am
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jul 1st, 2025 3:00 pm
Here's Why We're Watching Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation - Jun 26th, 2025 6:04 am
Zentalis Pharmaceuticals First Quarter 2025 Earnings: US$0.67 loss per share (vs US$0.14 profit in 1Q 2024) - May 16th, 2025 4:08 am
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress - May 14th, 2025 2:05 pm
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC - Apr 28th, 2025 6:00 am
Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting - Apr 23rd, 2025 2:05 pm
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates - Mar 26th, 2025 2:05 pm
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 - Mar 25th, 2025 2:40 pm
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - Mar 15th, 2025 9:25 am
Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - Mar 3rd, 2025 6:00 am
Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently - Feb 20th, 2025 10:21 pm
Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Feb 3rd, 2025 7:35 am